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ardiac Resynchronization Therapy: Caveat Medicus!
andeep R. Mehra, MD, FACC,* Barry H. Greenberg, MD, FACC†
ew Orleans, Louisiana; and San Diego, California
The device era in heart failure has been heralded by successes in the realm of pacemakers,
implantable defibrillators, and ventricular assist devices. In particular, the concept of cardiac
resynchronization therapy, which seeks to optimize ventricular contractility by decreasing
areas of focal dyssynchrony, is gaining wide acceptance. Recent trials of cardiac resynchro-
nization therapy have suggested that this treatment modality yields benefits that are reflected
in improved functional capacity, reversal of ventricular modeling, and decreased hospitaliza-
tions. Cardiac resynchronization device therapy exerts a substantial placebo effect, with
evidence of improved functional capacity and quality-of-life parameters in almost half of
those in the control group, probably as a result of device implantation. Furthermore, analysis
of the different trials suggests heterogeneity of response (differences in magnitude of observed
benefit between trials presumably enrolling similar heart-failure populations) and a large
non-responder rate (no improvement in functional capacity and well-being). The appropriate
approach to resynchronization must include much more than simple characteristics of device
implantation. We must detect the presence and precise location of mechanical dyssynchrony
and be able to find the technical location and place the pacing leads in the appropriate
position. Finally, we must be able to show evidence for sustained improvement in ventricular
dyssynchrony. Thus, the current approach to resynchronization represents a “best guess”
approach to achieving resynchronization by observation of surrogate responses. Continued
investigation to determine optimal approaches for achieving a beneficial clinical response is
essential to ensure that cardiac resynchronization therapy is offered to those most likely to
benefit. (J Am Coll Cardiol 2004;43:1145–8) © 2004 by the American College of
Cardiology Foundationi
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talidation of therapeutic strategies in heart failure (HF)
s proceeding at a rapid pace but with divergent out-
omes. On one hand, the neurohormonal model has faced
major obstacle, with accumulating evidence suggesting
hat additive pharmacologic treatments are unlikely to
ield incremental benefits beyond those achieved by
ntagonism of the renin-angiotensin-aldosterone and
drenergic systems (1). On the other hand, trials exam-
ning device therapy in HF that address electrical and
echanical aberrations by the application of pacemakers,
mplantable defibrillators, and ventricular assist devices
re demonstrating incremental success (2). In particular,
he concept of cardiac resynchronization therapy (CRT),
hich seeks to optimize ventricular contractility by de-
reasing areas of focal dyssynchrony, is gaining wide
linical acceptance (3). Although the scientific evidence
upporting this avenue of therapy is compelling, transla-
ion of this approach to the clinical realm requires some
aution. We wish to review the pitfalls of currently
vailable data, emphasize the complexity involved in
sing electrical conduction defects as a surrogate for
echanical dyssnchrony, and discuss technical aspects,
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Manuscript received March 10, 2003; revised manuscript received June 24, 2003,tccepted October 21, 2003.ncluding pacing site selection and programming of
ptimal settings.
O THE CLINICAL TRIALS CONCLUSIVELY SUPPORT
HE USEFULNESS OF CRT?
everal recent clinical trials have provided support for the
sefulness of cardiac resynchronization therapy using biven-
ricular pacing (4–7). Recent randomized clinical trials of
ardiac resynchronization therapy have suggested that ap-
lication of this treatment modality in severe systolic HF
espite optimal drug therapy yields benefits that result in
mproved functional capacity, reversal of ventricular remod-
ling, and decreased hospitalizations (4–7). Indeed, a recent
eta-analysis of these trials has even suggested decreased
eaths from progressive HF as a consequence of cardiac
esynchronization (8). More recently, the COMPANION
Comparison of medical therapy, pacing, and defibrillation
n HF) trial results were made available (9). This trial
nrolled patients with New York Heart Association
NYHA) functional class III or IV symptoms of HF despite
aximized medical therapy (left ventricular [LV] ejection
raction 35%, LV end-diastolic diameter 6 cm). Other
nclusion criteria included a QRS duration 120 ms and a
R interval 150 ms. The trial had three treatment arms:
ne of five patients was to receive optimal pharmacologic
herapy, two of five were to receive optimal pharmacologic
herapy plus biventricular pacing, and the remaining two of
he five were to receive biventricular pacing, plus backup
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CRT in Heart Failure April 7, 2004:1145–8mplantable cardioverter-defibrillator therapy. In contrast to
revious trials, this study was powered to evaluate a primary
nd point of combined all-cause mortality and hospitaliza-
ion. Peak oxygen consumption was the other (functional)
rimary end point. Secondary end points included all-cause
ortality, cardiac mortality, exercise performance, NYHA
unctional class, quality of life, and the 6-min walk test
istance. Data were analyzed using an intention-to-treat
pproach. A total of 1,520 patients were randomized, and
,080 patients were implanted with a CRT pacer or defi-
rillator (CRT/D). A total of 118 patients failed initial
mplant (88% implant success for CRT and 92% for
RT/D). Left ventricular lead dislodgment was seen in 2%
nd 2.5% in the CRT and CRT/D groups, respectively. As
ompared to patients treated with medical therapy only,
here was a statistically significant event rate reduction in
he primary combined end point of total hospitalization and
otal mortality at one year in the CRT and CRT/D groups
odds ratio 0.82, p  0.05 and 0.81, p  0.015, respectively),
s well as in the combined end point of hospitalization for
HF and death (odds ratio 0.64 and 0.60, respectively, p 
.05). Mortality at 1 year decreased nonsignificantly by 24%
p  0.121, ns) in the CRT group, and significantly by 43%
p  0.002) in the CRT/D group.
Although these lines of evidence are encouraging, several
imitations of this database deserve mention. First, place-
ent of the device exerts a substantial placebo effect, with
vidence of improved functional capacity and quality-of-life
arameters in those randomized to the control group,
robably as a result of device implantation. Second, most of
hese investigations randomized patients only after initial
uccessful device implantation, thereby limiting the useful-
ess of the final results through a lack of a “true” intent-to-
reat study design. Finally, an analysis of the benefits
emonstrated among the different trials suggests remarkable
eterogeneity of response (differences in magnitude of
bserved benefit between trials presumably enrolling similar
F populations) and a large non-responder rate (no im-
rovement in functional capacity and well-being). Although
he current clinical trial evidence definitely supports the
proof of concept” that CRT is of benefit, translating this
herapeutic approach to general practice might be fraught
ith a number of technical obstacles that are unlikely to
llow accurate replication of observed within-trial effects to
he population at large.
Abbreviations and Acronyms
CRT  cardiac resynchronization therapy
CRT/D  cardiac resynchronization therapy pacer or
defibrillator
HF  heart failure
LV  left ventricle/ventricular
NYHA  New York Heart AssociationlMPLICATIONS OF THE PLACEBO RESPONSE TO CRT
andomized controlled trials that include a placebo group
epresent the current standard in clinical trial design. As
ith drug therapy, surgical devices are well known to evoke
significant placebo response in patients. Thus, the mag-
itude of benefit due to an intervention is typically possible
y noting the “placebo-subtracted” efficacy (intervention
roup minus control group benefits). A critical analysis of
he placebo-subtracted benefits of CRT on functional ca-
acity and quality-of-life parameters suggest significant
eterogeneity (differences in benefit varying by almost 50%)
n different trials that presumably enroll similar patient
opulations that receive the same CRT device. Although
ariable benefits occur with medications as well, device
herapy needs to be held to a higher standard because of the
dditional variable of technical skills of the implanting
hysician and device complications. The observed placebo
esponse to CRT varies between 38% to nearly 50% in
arious trials, whereas the placebo-subtracted improvement
n NYHA functional capacity (by 1 functional class) is in
he realm of 15% to 30% (5,6). Interestingly, the heteroge-
eity of benefit among the different trials cannot be simply
xplained by criteria of patient enrollment nor by the device
sed to achieve CRT. The implication of this observation is
hat the large majority of the observed functional improve-
ents in responders to CRT is in fact dependent on the
lacebo response that is evoked by the implantation and not
ecessarily by the actual process of resynchronization.
Other lines of evidence pointing to the heterogeneity of
esponse are also forthcoming. Similarly, although the
rimary end point in one trial of an improvement in 6-min
alk test was significantly achieved, a separate trial failed to
emonstrate any benefit in that particular parameter (5,6).
eart failure hospitalizations were noted to decrease with
esynchronization therapy in one trial but not in others (8).
he meta-analysis by Bradley et al. (8) that evaluated
ombined results from four randomized trials (number of
nrolled patients ranged from 58 to 554 per trial, n 1,634)
f cardiac resynchronization therapy suggested that deaths
rom progressive HF were decreased, yet no benefit on
ll-cause mortality was noted and not enough information
n all-cause hospitalizations was available to generate an
dequate composite analysis. The fact that the magnitude of
enefit is not consistent across the spectrum of clinical trials
s disturbing. Because the benefit of cardiac resynchroniza-
ion therapy must likely ensue for achieving mechanical
ynchronicity, it is possible that restoration of mechanical
ynchrony is not a consistent event. Why might this be so?
HERE IS THE RESYNCHRONIZATION IN CRT?
lthough the technique of multisite pacing is most often
eferred to as resynchronization therapy, the typical process
nvolves selection of patients based on HF severity, surface
lectrocardiographic QRS widening, and evidence of under-
ying cardiac enlargement with consequent systolic dysfunc-
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April 7, 2004:1145–8 CRT in Heart Failureion. This is then followed by the technical implant via
tandardized techniques, and success of the procedure is
eralded by completion of device placement. The appropri-
te approach to resynchronization must include much more
han these simple characteristics. First, we must be able to
emonstrate the presence and precise location of mechanical
yssynchrony. Then, we must be able to technically locate
nd position the pacing leads in the appropriate position so
s to improve the dyssynchronous contractility. Finally, we
ust be able to show evidence for sustained improvement in
entricular dyssynchrony. Thus, the current approach to
esynchronization represents a “best guess” approach to
chieving resynchronization by observation of surrogate
esponses.
echnical limitations. One of the major technical limita-
ions to achieving success with resynchronization therapy
ies in the anatomic variability of the coronary sinus anat-
my as well as the experience of the implanting physician
10,11). In this regard, coronary sinus anatomy often re-
uires delineation by venography and carries up to a 6% risk
f venous dissection or perforation as reported in the trials
hat presumably were conducted by experienced investiga-
ors who underwent supervision and implant training (4–
,12). Furthermore, despite the experience levels of the trial
nvestigators, the rate of unsuccessful implants ranged from
% to 13% (4–7). One can imagine, therefore, that if these
ndings were to be translated to general practice, the net
enefit noted in responder rates would necessarily be de-
reased by the magnitude of unsuccessful implants and
echnical complications.
oes a wide QRS always denote dyssynchrony? The
ecognition that surface electrical conduction defects repre-
ented by a widened QRS complex are associated with
echanical asynchrony is well accepted (3). In particular,
his electrocardiographic finding has been linked with an
ndependent impact on cardiac mortality, and the severity of
his abnormality tends to correlate with worse outcome (13).
owever, the ability of a wide QRS interval to consistently
redict the presence, magnitude, and location of mechanical
synchrony is questionable. Thus, benefits of resynchroni-
ation therapy are predicted neither by the severity of QRS
idening nor by the magnitude of decrease in QRS width
fter resynchronization (14). An important investigation by
urrichio et al. (15) compared pacing sites in relation to
ercent change in rate of change of pressure over time
dP/dt). Increases in systolic function were significantly
reater at mid-lateral LV sites compared to any other region
hat could be accessed via the coronary sinus. In addition,
acing at apical or mid-anterior sites increased LV dP/dt
ignificantly more than pacing at the base. It has also been
oted that the maximum short-term benefit at any site
ccurs with customizing the atrioventricular delay to an
ndividual. If indeed an individualized atrioventricular delay
s essential for achieving at least some of the proposed
enefits of cardiac resynchronization therapy, one could
nfer that the presence of underlying atrial fibrillation could nreate a situation wherein it might be difficult to maximize
ynchronicity. The implications of this finding are impor-
ant because a substantial number of patients with severe
F present with concomitant atrial fibrillation and most
tudies of cardiac resynchronization therapy have excluded
his population (4 –7). Another provocative study by
eclercq et al. (16) provided evidence that LV pacing alone
ay lengthen the QRS interval but yet resynchronize the
echanical function of the ventricle in a similar fashion, as
oes biventricular pacing. Left ventricular pacing starts with
ocal lateral wall contraction that advances slowly, with
rominent contraction appearing next in the septum. The
nvestigators speculate that the mechanism for this inherent
lectromechanical paradox might arise from the creation of
focal area of slowly contracting muscle in the mid-lateral
all.
redictors of response to CRT. In evaluating the rela-
ionship of baseline ventricular configuration and outcome
rom resynchronization therapy, Pitzalis et al. (17) sug-
ested that the mere use of underlying LV volume and
jection fraction might not be an adequate predictor of
esponse to resynchronization therapy, and a baseline mea-
ure of mechanical contractile dyssynchrony is needed to
dentify those patients most likely to benefit. In this study,
he investigators used septal-to-posterior wall-motion delay
s an echocardiographic parameter of mechanical asyn-
hrony and showed that only patients with prolongation in
his measured index achieved reversal of LV remodeling.
sing tissue Doppler imaging, Sogaard et al. (18) have
onvincingly demonstrated that the site and degree of
echanical asynchrony can vary from patient to patient and
n particular is influenced by the underlying etiology of
isease, whether ischemic or non-ischemic. Thus, it is
onfirmed that a QRS width on the electrocardiogram
epresents at best a crude measure of underlying mechanical
synchrony, cannot be expected to provide an adequate
eans of predicting response to resynchronization therapy,
nd definitely cannot be used to guide appropriate lead
lacement.
The definition of a successful implant therefore should
ot be narrowed to merely accepting device implantation,
ut must include demonstration and identification of the
recise area of ventricular asynchrony, followed by position-
ng the coronary sinus catheter in the optimal location to
ackle the mechanical dyssynchronous contractility.
XTRAPOLATION OF CRT TO MILD HF
s with any therapeutic application, the urge to extrapolate
otential for benefit to less morbidly ill populations exists
ut must be resisted. It has been observed that even trial
nvestigators tend to over classify severity of functional
mpairment in HF and a gap exists in the intended severity
f illness and final population enrolled. Thus, trials of
eta-blockers that purported to represent severe HF were
oted to have enrolled populations in whom the observed
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CRT in Heart Failure April 7, 2004:1145–8ortality rates in the control groups were far less than those
hat would be expected based on the enrollment criteria of
everity (19,20). Furthermore, the tendency to extrapolate
vidence to less ill patients with HF might be harmful. In
his regard, a recent investigation by Bozkurt et al. (21)
rovided evidence for a rising rate of inappropriate prescrip-
ions for spironolactone in less severe forms of HF, with
onsequent increases in complication rates beyond those
eported in the clinical trials with this agent. Unlike drug
herapy, which can be followed and the offending drug
topped before potential harm, the clinical cost of devices is
ypically front-loaded, with reported mortality rates ranging
rom 0.3% to 2.1% and other major complications including
ascular complications (6%), infection (1%), lead dislodge-
ent or loss of capture (7%), and technically unsuccessful
mplants (8% to 13%) (4–7).
In view of this, it is appropriate to consider resynchroni-
ation therapy in patients with severe systolic HF in spite of
tructured use of optimal pharmacologic therapy. Ideally,
bjective measures of reduced functional capacity on either
6-min walk or cardiopulmonary exercise stress test should
e used to confirm the limitation in exercise capacity. This
ould ensure the application of such therapy to a patient
opulation in whom the risk-benefit ratio of device therapy
ight be more justifiable. Thus, the decision to perform
ardiac resynchronization therapy should not be taken
ightly, and patients should be clearly informed of the
otential risks and heterogeneous response expectation.
One of the most important advances in CRT must accrue
rom diminishing the implantation risks and redefining
successful” implantation to include correlation of the site
nd magnitude of mechanical asynchrony. As more infor-
ation regarding mechanisms of benefit from resynchroni-
ation accumulate and patient selection evolves (22,23),
urther large-scale, adequately powered clinical trials will be
eeded to assess effects on morbidity and mortality as well as
unctional outcomes in patients with less severe HF. Finally,
ontinued investigation to improve pacing and sensing
apabilities of the devices and to determine optimal ap-
roaches for achieving a beneficial clinical response are
ssential to ensure that CRT is offered to those most likely
o benefit.
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mehra@ochsner.org.
EFERENCES
1. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a
crossroad: are there limits to the neurohormonal model? J Am Coll
Cardiol 2003;41:1606–10.
2. McMurray J, Pfeffer MA. New therapeutic options in congestive heart
failure: part II. Circulation 2002;105:2223–8.3. Tavazzi L. Ventricular pacing: a promising new therapeutic strategy in
heart failure. For whom? Eur Heart J 2000;21:1211–4.
4. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biven-
tricular pacing in patients with heart failure and intraventricular
conduction delay. N Engl J Med 2001;344:873–80.
5. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchroniza-
tion in chronic heart failure. N Engl J Med 2002;346:1845–53.
6. Young JB, Abraham WT, Smith AL, et al., Multicenter InSync ICD
Randomized Clinical Evaluation (MIRACLE ICD) Trial Investiga-
tors. Combined cardiac resynchronization and implantable cardiover-
sion defibrillation in advanced chronic heart failure: the MIRACLE
ICD trial. JAMA 2003;289:2685–94.
7. Summary of Safety and Effectiveness: Guidant CONTAK CD
CRT-D System [report] U.S. Food and Drug Administration Web
site. Available at: http://www.fda.gov/cdrh/pdf/p010012.html. Ac-
cessed June 4, 2003.
8. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchroni-
zation and death from progressive heart failure. A meta-analysis of
randomized controlled trials. JAMA 2003;289:730–40.
9. Bristow MR, Saxon LA, Boehmer J, et al., for the COMPANION
Investigators. Cardiac resynchronization therapy (CRT) reduces hos-
pitalizations and CRT an implantable defibrillator (CRT/D) reduces
mortality in chronic heart failure: preliminary results of the COM-
PANION Trial. ACC Late Breaking Trials, 52nd Annual Scientific
Session, Chicago, IL, March 30 to April 2, 2003.
0. Artrip JH, Sukerman D, Dickstein ML, Spotnitz HM. Transesoph-
ageal echocardiography guided placement of a coronary sinus pacing
lead. Ann Thorac Surg 2002;74:1254–6.
1. Ortale JR, Gabriel EA, Iost C, Marquez CQ. The anatomy of the
coronary sinus and its tributaries. Surg Radiol Anat 2001;23:15–21.
2. Gras D, Cebron JP, Brunel P, Leurent B, Banus Y. Optimal
stimulation of the left ventricle. J Cardiovasc Electrophysiol 2002;13
Suppl:S57–62.
3. Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block
is associated with increased 1-year sudden and total mortality rate in
5,517 outpatients with congestive heart failure: a report from the
Italian network on congestive heart failure. Am Heart J 2002;143:
398–405.
4. Vogt J, Krahnefeld O, Lamp B, et al. Electrocardiographic remodeling
in patients paced for heart failure. Am J Cardiol 2000;86 Suppl
1:K152–6.
5. Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber
and atrioventricular delay on acute systolic function of paced patients
with congestive heart failure. The Pacing Therapies for Congestive
Heart Failure Study Group. The Guidant Congestive Heart Failure
Research Group. Circulation 1999;99:2993–3001.
6. Leclercq C, Faris O, Tunin R, et al. Systolic improvement and
mechanical resynchronization does not require electrical synchrony in
the dilated failing heart with left bundle-branch block. Circulation
2002;106:1760–3.
7. Pitzalis MV, Iacoviello M, Romito R, et al. Cardiac resynchronization
therapy tailored by echocardiographic evaluation of ventricular asyn-
chrony. J Am Coll Cardiol 2002;40:1615–22.
8. Sogaard P, Egeblad H, Pedersen AK, et al. Sequential versus simul-
taneous biventricular resynchronization for severe heart failure: evalu-
ation by tissue Doppler imaging. Circulation 2002;106:2078–84.
9. Packer M, Coats AJ, Fowler MB, et al., for the Carvedilol Prospective
Randomized Cumulative Survival Study Group. Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med 2001;344:
1651–8.
0. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a random-
ised trial. Lancet 1999;353:9–13.
1. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate
use of spironolactone in heart failure: when an old medicine spirals out
of new guidelines. J Am Coll Cardiol 2003;41:211–4.
2. Breithardt OA, Sinha AM, Schwammenthal E, et al. Acute effects of
cardiac resynchronization therapy on functional mitral regurgitation in
advanced systolic heart failure. J Am Coll Cardiol 2003;41:765–70.
3. Nowak B, Sinha AM, Schaefer WM, et al. Cardiac resynchronization
therapy homogenizes myocardial glucose metabolism and perfusion in
dilated cardiomyopathy and left bundle branch block. J Am Coll
Cardiol 2003;41:1523–8.
